Global Non-invasive Vaccine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Non-invasive Vaccine Market Research Report 2024
Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
According to Mr Accuracy reports’s new survey, global Non-invasive Vaccine market is projected to reach US$ 3909.1 million in 2029, increasing from US$ 2670 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-invasive Vaccine market research.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non-invasive Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type
Oral Vaccine
Nasal Spray Vaccine
Public
Private
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Non-invasive Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Non-invasive Vaccine market is projected to reach US$ 3909.1 million in 2029, increasing from US$ 2670 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-invasive Vaccine market research.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non-invasive Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type
Oral Vaccine
Nasal Spray Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Non-invasive Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices